Reduction of intracranial pressure by nimodipine in experimental pneumococcal meningitis

Citation
R. Paul et al., Reduction of intracranial pressure by nimodipine in experimental pneumococcal meningitis, CRIT CARE M, 28(7), 2000, pp. 2552-2556
Citations number
35
Categorie Soggetti
Aneshtesia & Intensive Care
Journal title
CRITICAL CARE MEDICINE
ISSN journal
00903493 → ACNP
Volume
28
Issue
7
Year of publication
2000
Pages
2552 - 2556
Database
ISI
SICI code
0090-3493(200007)28:7<2552:ROIPBN>2.0.ZU;2-D
Abstract
Objective: In this study, we investigated the effect of the calcium channel blocker nimodipine on the pathophysiologic alterations during experimental pneumococcal meningitis in rats. Design: Prospective, controlled trial. Setting: University center, animal laboratory. Subjects: A total of 37 adult male Wistar rats (290-360 g), Interventions: Meningitis was induced by the intracisternal injection of pn eumococci, Anaesthetized animals were treated with nimodipine (30 mu g/kg/h r iv) either 15 mins before (pretreatment) or 5 hrs after (posttreatment) p neumococcal challenge. Measurements and Main Results: Treatment with nimodipine (30 mu g/kg/hr iv) significantly decreased the pneumococci-induced rise in intracranial press ure irrespective of the time of administration. Moreover, pretreatment with nimodipine also significantly reduced the pneumococci-induced increase in cerebrospinal fluid white blood cell counts. To ascertain possible mechanis ms of the beneficial effect, we investigated the influence of nimodipine on reactive oxygen species (ROS) and cytokine production. By using lucigenin- enhanced chemiluminescence, we found that nimodipine inhibited the pneumoco cci-induced production of ROS in human whole blood samples, Moreover, nimod ipine significantly reduced the pneumococci-induced increase in the interle ukin-6 concentrations in the cerebrospinal fluid. Conclusion: Our results demonstrate that nimodipine decreases the intracran ial pressure during experimental pneumococcal meningitis, possibly by mecha nisms including the reduction of ROS and interleukin-6 production.